Influenza vaccines in children

Area of Science:

• Pediatric infectious diseases
• Vaccinology
• Public health

Background:

• Influenza poses significant health risks to children, leading to hospitalizations and increased healthcare utilization.
• Young children and those with chronic conditions are particularly vulnerable to severe influenza outcomes.
• Physician visits and antibiotic prescriptions increase during influenza season for pediatric populations.

Purpose of the Study:

• To review the safety, immunogenicity, and efficacy of influenza vaccines in children.
• To compare inactivated influenza vaccine with investigational live-attenuated influenza vaccine (LAIV).
• To inform potential recommendations for routine influenza vaccination in children.

Main Methods:

• Review of clinical trials and postlicensure data on influenza vaccines in pediatric populations.
• Evaluation of safety and tolerability profiles of different vaccine types.
• Assessment of immunogenicity and efficacy data from controlled studies.

Main Results:

• Trivalent inactivated influenza vaccine is well-tolerated and effective in children, supported by extensive clinical and postlicensure data.
• Investigational live-attenuated influenza vaccine (LAIV) administered intranasally shows promise, with demonstrated tolerability and efficacy in a large trial for children aged 15-71 months.
• Both vaccine types show favorable safety and efficacy profiles in pediatric populations.

Conclusions:

• Influenza vaccines are a critical tool for protecting children against seasonal influenza.
• Live-attenuated influenza vaccine (LAIV) offers an alternative administration route and demonstrates efficacy, pending further safety and coadministration data.
• Future recommendations may expand routine influenza vaccination for young children based on ongoing research.